With the DEA recommendtion ARNA should be @ $11 at least.
Finally, news that the DEA recommended Schedule 4 classification for Arena's (ARNA) Belviq on December 28, 2012. This is a classification similar to widely used insomnia drugs Ambien, Lunesta, and Sonata, although Belviq likely has even less potential for abuse than these selective benzodiazepines. Schedule 4 will likely not have a negative impact on sales potential for Belviq. The obesity drug was approved June 27, 2012. There was considerable excitement last summer, Arena shares peaked around $13.50 per share, only to slide. There has been an uptrend recently, either based on the upcoming scheduling /European approval or the lack of robust initial sales of competing Qsymia by Vivus (VVUS). Share prices of Orexigen (OREX), with its obesity drug Contrave scheduled for possible approval in 2014, has also been on an uptrend.